Research interests include Esophageal Cancer Research and Treatment, Hepatocellular Carcinoma Treatment and Prognosis, Esophageal and GI Pathology, and Head and Neck Cancer Studies.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study